UroToday2d
Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer.
To investigate the expression patterns of Nectin-4, the target molecule of the antibody-drug conjugate enfortumab vedotin (EV), in relation to histological and molecular subtypes of urothelial bladder ...
UroToday3d
Prospective validation study of a combined urine and plasma test for predicting high-grade prostate cancer in biopsy naïve men.
Early and accurate diagnosis of prostate cancer (PC) is crucial for effective treatment. Diagnosing clinically insignificant cancers can lead to overdiagnosis and overtreatment, highlighting the ...
UroToday3d
Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review.
The purpose of this systematic review was to evaluate the role of PSMA PET/CT in intermediate-risk prostate cancer (PCa) patients, to determine whether it could help improve treatment strategy and ...
UroToday3d
Evaluating the feasibility of AI-predicted bpMRI image features for predicting prostate cancer aggressiveness: a multi-center study.
To evaluate the feasibility of utilizing artificial intelligence (AI)-predicted biparametric MRI (bpMRI) image features for predicting the aggressiveness of prostate cancer (PCa). A total of 878 PCa ...
UroToday3d
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, ...
UroToday4mon
Prostate Cancer
Rates of PSMA PET Staging and Positivity in Newly Diagnosed Prostate Cancer in a National Health Care System. January 7, 2025 Prostate Cancer Patient With Lymph-node Metastasis Treated Only With ...
UroToday3d
Comprehensive Genetic Profile of Chinese Muscle-Invasive Bladder Cancer Cohort.
The aim of our study was to characterize the spectrum of mutations in muscle-invasive bladder cancer (MIBC) in the Chinese population, identifying mutational features and exploring potential ...
UroToday13d
Comparing Autologous and Mesh Slings for Stress Incontinence Efficacy and Safety - Ariana Smith
Comparing Autologous and Mesh Slings for Stress Incontinence Efficacy and Safety - Ariana Smith ...
UroToday6d
Why wasn't mirabegron chosen for the first year of the CMS negotiation program?
Importance: The most used overactive bladder (OAB) medications are anticholinergics, which professional societies recommend avoiding in older patients given dementia risk. Cost prevents patients from ...
UroToday6d
A Novel Machine Learning-Based Predictive Model of Clinically Significant Prostate Cancer and Online Risk Calculator - Beyond the Abstract
This recent publication presents a novel machine learning-based predictive model for clinically significant prostate cancer, along with an online risk calculator. The model was developed using a ...
UroToday6d
Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek® in adult patients with overactive bladder.
Mirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron ...
UroToday6d
Predicting Elevated Postvoid Residual Urine Volume Following OnabotulinumtoxinA Treatment for Overactive Bladder: A Pilot Study.
To evaluate possible predictors of elevated postvoid residual volume (PVR) following onabotulinumtoxinA administration in patients with idiopathic overactive bladder (OAB), a condition that may ...